Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2012 / Cilt: 58 - Sayı: 4

Dirençli pyoderma gangrenosumda infliksimab tedavisi: Bir olgu sunumu

Infliximab treatment in resistant pyoderma gangrenosum: A case report

Pages
332–334
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Biological agents (anti-TNF) may be alternative treatmentoptions in patients with resistant PG.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosisconsisting of nodules and pustules that ulcerate.
📊
Key Findings & Data:Pyoderma gangrenosum isassociated with autoimmune disorders such as inflammatory bowel disease,spondyloarthritis, and rheumatoid arthritis.
💡
Conclusion & Impact:Biological agents (anti-TNF) may be alternative treatmentoptions in patients with resistant PG.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosisconsisting of nodules and pustules that ulcerate. Pyoderma gangrenosum isassociated with autoimmune disorders such as inflammatory bowel disease,spondyloarthritis, and rheumatoid arthritis. In mild disease, therapy consists oflocal wound care and topical or intralesional corticosteroids. For more severedisease, systemic agents are necessary. Herein, we present the case of a patientwith steroid resistant pyederma gangrenosum associated with ulcerative colitisand ankylosing spondylitis who responded well to infliximab, a tumor necrosisfactor blocker. Biological agents (anti-TNF) may be alternative treatmentoptions in patients with resistant PG.

Özet

Pyoderma gangrenosum (PG), püstüler ve nodüler ülserlerle seyreden nadir bir nötrofilik dermatozdur. Pyoderma gangrenosum inflamatuvar barsak hastalığı,romatoid artrit, spondiloartrit gibi otoimmün hastalıklarla ilişkili olabilir. Hafif hastalığın tedavisi lokal yara bakımı ve topikal veya intralezyonel kortikosteroidlerden oluşur. Daha şiddetli bir hastalık için sistemik ajanlar gereklidir. Bu sunumda ülseratif kolitle ilişkili ankilozan spondilitli bir vakanınyüksek doz steroide dirençli pyoderma gangrenosum lezyonununun bir tümör nekrozis faktör blokeri olan infliksimab tedavisine yanıtını sunduk. Biyolojik ajanlar dirençli PG tedavi alternatifi olabilirler.

🔖

Cite This Article

KURU, Ö., DURMAZ, Y., CİL, E. E., BİLGİCİ, A. (2022). Dirençli pyoderma gangrenosumda infliksimab tedavisi: Bir olgu sunumu. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 58 - Sayı: 4, 332–334. https://ajindex.com/articles/628939

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Heffernan MP Anadkat MJ, Smith DI. Adalimumab Treatment for Pyoderma Gangrenosum. Arch Dermatol 2007;143:306-8
  2. De la Morena F Martín L, Gisbert JP Fernandez Herrera J, Goiriz R. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis 2007;13:509-10
  3. Abela CB, Soldin M, Gateley D. Pyoderma gangrenosum-Case report. Br J Oral Maxillofac Surg 2007;45:328-30
  4. Reguiaï Z, Grange F The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol 2007;8:67-77
  5. Brooklyn TN, Dunnill MG, Shetty A, Bowden JJ, Williams JD, Griffiths CE, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut 2006;55:505-9
  6. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellström PM. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-α blockade with infliximab. Scand J Gastroenterol 2002;37:1108-10
  7. Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat 2011;22:261-5. doi: 10.3109/09546631003797106
  8. Rogge FJ, Pacifico M, Kang N. Treatment of pyoderma gangrenosum with the anti-TNFa drug e Etanercept. J Plast Reconstr Aesthet Surg 2008;61:431-3.